Enlaza

Enlaza Therapeutics

This biotechnology company develops covalent protein medicines that form irreversible bonds with disease targets to treat patients with cancer and autoimmune conditions.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

HYKU Biosciences

This biotechnology company develops precision covalent small-molecule medicines targeting disease-driving proteins to treat patients with cancer and other illnesses.

Ligature Therapeutics

This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.

Catena Bio

This biotechnology firm develops protein conjugation technology and multi-payload therapeutic conjugates for biopharmaceutical companies to treat oncology and autoimmune diseases.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.